On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company's pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus. The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg. The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events. In addition, there were no significant observations noted in laboratory assessments, physical exams, or electrocardiograms. The company is currently manufacturing drug product for the multiple ascending dose (MAD) cohorts of the study with enrollment expected to begin in the fourth quarter of 2024.
